government for use in the United States
A five-day course of molnupiravir, the new medicine being hailed as a “ huge advance ” in the treatment of Covid-19, costs $17
government has paid around $530 for a 5-day course of Paxlovid, $700 per five-day course of molnupiravir, and $2,100 for a course of sotrovimab - the lone available antibody treatment Today, the U
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating
Medicare coverage and pricing details for Molnupiravir
Please review more information, including product safety information and information about authorized use in your country, by selecting your region from the list below
Los datos principales que respaldan esta autorización EUA para molnupiravir provienen de MOVe-OUT, un ensayo clínico aleatorizado, doble ciego y controlado con placebo que estudia molnupiravir The other oral antiviral drug Paxlovid, a combination of nirmatrelvir and ritonavir, has received EUA by US-FDA at the same time of Molnupiravir approval
74
com
Molnupiravir is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in non-hospitalized patients who are at high risk for progression to severe COVID-19 (eg, hospitalization, death) or in patients for whom other
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only
Paxlovid combines two medications: 2 tablets of nirmatrelvir (150 mg) and 1 tablet of ritonavir (100 mg)
Commercial ordering for the treatments is set to start on Nov
We assumed a treatment regimen of 800 mg molnupiravir twice daily 5 days (10 doses total), as in the Phase 3 MOVe-OUT trial
1 million sold to the US, 1
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO™ (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual with COVID-19
3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14
As this is a new medicine, there is little safety data